Importantly, the administration of the GM-CSF neutralising antibody, lenzilumab, has been observed to reduce symptoms of both CRS and ICANS, whilst promoting CAR-T cell activation (40). This evidence concerns the gene CSF2 and congenital rubella syndrome.